NovMetaPharma Co., Ltd. (XKON:229500)
South Korea
· Delayed Price · Currency is KRW 8,890.00
-250.00 (-2.74%)
At close: Mar 9, 2026
NovMetaPharma Company Description
NovMetaPharma Co., Ltd. engages in the development and sale of drugs to treat metabolic and fibrotic diseases in South Korea.
It is developing Cyclo-Z, which is in phase 2 clinical stage; and CHP that is in phase 1 clinical stage for the treatment of diabetic kidney disease, obesity, and rare conditions, including FSHD and DMD.
The company was formerly known as PNC MetaPharm Co., Ltd. and changed its name to NovMetaPharma Co., Ltd. in May 2015.
NovMetaPharma Co., Ltd. was incorporated in 2010 and is headquartered in Seoul, South Korea.
NovMetaPharma Co., Ltd.
| Country | South Korea |
| Founded | 2010 |
| Industry | Biological Products, Except Diagnostic Substances |
| CEO | Sun-Wook Hwang |
Contact Details
Address: Trees Building Seoul, 06050 South Korea | |
| Phone | 82 2 538 1893 |
| Website | novmeta.com |
Stock Details
| Ticker Symbol | 229500 |
| Exchange | Korea New Exchange |
| Fiscal Year | January - December |
| Reporting Currency | KRW |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Sun-Wook Hwang | Chief Executive Officer |